News

EMA Reverses Opinion on Delamanid for MDR-TB

Source: European Medicines Agency http://www.ema.europa.eu

On 21 November 2013, the Committee for Medicinal Products for Human Use (CHMP) recommended the granting of a conditional marketing authorisation for the medicinal product Deltyba for the treatment of lung infections due to multidrug-resistant tuberculosis when alternative treatments cannot be used due to resistance or intolerance. The company that applied for authorisation is Otsuka Novel Products GmbH.

On 25 July 2013, the CHMP had originally adopted a negative opinion for Delamanid in multidrug-resistant tuberculosis. At the request of the applicant, the CHMP started a re-examination of its opinion. Following the re-examination, the CHMP adopted a final positive opinion on 21 November 2013 recommending the granting of a conditional marketing authorisation for Deltyba, but restricting its use to treatment of tuberculosis affecting the lungs and to situations where alternative treatments cannot be used due to resistance or intolerance. Click here to to download the news release from EMA.

Additional Coverage:

CHMP Recommends Otsuka’s Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)

Tuberculosis Drug Wins Backing of European Panel (WSJ)

View Delamanid on Global Pipeline–http://www.newtbdrugs.org/project.php?id=136

More News
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...